Comparative Pharmacology
Head-to-head clinical analysis: DITROPAN XL versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DITROPAN XL versus HICON.
DITROPAN XL vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxybutynin is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing detrusor muscle contraction and bladder smooth muscle spasm, thereby increasing bladder capacity and decreasing urge incontinence.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Oral: 5 to 10 mg once daily; maximum 30 mg once daily.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
The terminal elimination half-life of oxybutynin is approximately 12-13 hours for the immediate-release formulation, but for DITROPAN XL, due to its extended-release profile, the effective half-life is extended, allowing once-daily dosing. Clinical context: steady-state is achieved within 3 days of dosing.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Approximately 50% of the administered dose is excreted in urine as unchanged drug and its active metabolite, N-desethyloxybutynin, with the remainder excreted in feces via biliary elimination.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic